Shows
OncLive® On AirCollaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCMIn today’s episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Department of Surgery at Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical Sc...2025-06-1009 minOncLive® On AirMultidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCMIn today’s episode, we had the pleasure of speaking with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026 president-elect of ASCO. Dr Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts.
In our exclusive interview, Dr...2025-06-0312 min
ASTRO JournalsRed Journal Podcast: Cover Art at the Red JournalSend us a textEditor in Chief Sue Yom hosts four of our artists – Jen Bellon, our journal’s Art Editor, who was previously at Dana Farber Cancer Institute/Brigham & Women’s Hospital, and now works as an independent art consultant; Annie Lavigne, Assistant Professor of Radiation Oncology at Johns Hopkins University; Josh No, Attending Physician at Kaiser Permanente; and Tony Orlina, Lead Dosimetrist at Dana Farber Cancer Center. They discuss the role of art in their lives, stories of their Red Journal cover artworks, and what they see as the role of art in medicine.2025-05-2347 min
BornCuriousStorytelling and Grief in Palliative CareThere is a long-held belief in the medical field that doctors should maintain a professional distance from their patients. But it’s only human to be affected by one’s everyday experiences—and for professionals who work with serious illness, these experiences can range from distressing to profound. In this episode, a collaboration with Grief Is a Sneaky Bitch, we discover how the Palliative Story Exchange uses storytelling to center human connection and meaning in this setting.
Released on May 22, 2025.
Episode Transcript
Guest Host
Lisa Keefauver is a social worker, a grief ac...2025-05-2252 min
Audio Journal of Oncology PodcastAdding Perioperative Pembrolizumab to Standard of Care Improves Outcomes in Patients with Newly Diagnosed Head and Neck CancersInterviews with:
Ravindra Uppaluri, MD PhD, Director of Head and Neck Surgical Oncology, Dana Farber Brigham Cancer Center, Boston MA;
And: Ryan B Corcoran MD PhD, Director of the gastrointestinal cancer program, Massachusetts General Hospital Cancer Center, Associate Professor of Medicine Harvard Medical School and Co-Chair of the American Association for Cancer Research Clinical Trials Committee.
CHICAGO, USA—Perioperative immunotherapy, using the PD-1 blocker pembrolizumab both before and after surgery, has been investigated in patients with newly diagnosed head and neck cancers in the phase three KEYNOTE-689 study. Findings were reported at the 2025 An...2025-05-0113 min
Patient from HellThe Rise of Young-Onset Colorectal Cancer: Environmental Factors and Screening StrategiesIn this episode, Dr. Tejas Jayakrishnan discusses the rising incidence of young onset colorectal cancer (CRC) and the potential environmental factors contributing to this trend. The conversation delves into the importance of screening protocols, the challenges faced in early detection, and the role of education in increasing awareness and understanding of cancer risks. Dr. Jayakrishnan emphasizes the need for tailored approaches in patient care, particularly for younger patients, and highlights ongoing research efforts aimed at improving outcomes in this demographic.About Our Guest:Dr. Thejus Jayakrishnan is a gastrointestinal medical oncologist at Dana-Farber Cancer Institute...2025-04-2343 min
ASTRO JournalsRed Journal Podcast: Cover Art at the Red JournalEditor in Chief Sue Yom hosts four of our artists – Jen Bellon, our journal’s Art Editor, who was previously at Dana Farber Cancer Institute/Brigham & Women’s Hospital, and now works as an independent art consultant; Annie Lavigne, Assistant Professor of Radiation Oncology at Johns Hopkins University; Josh No, Attending Physician at Kaiser Permanente; and Tony Orlina, Lead Dosimetrist at Dana Farber Cancer Center. They discuss the role of art in their lives, stories of their Red Journal cover artworks, and what they see as the role of art in medicine.2025-04-2247 min
OncLive® On AirStrong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMScIn this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Ann S. LaCasce, MD, MMSc, an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology. LaCasce shares her journey into hematologic oncology, shaped by early mentors—including her father—and how a passion for art history sparked her interest in pattern recognition and morphology, which are skills central to lymphoma diagnosis.
Their discussion explores key adva...2025-03-2620 min
SurgOnc Today®WICS Finance Series: Episode 4 - Organizational Fund FlowListen to the final episode of this 4-part Women in Cancer Surgery podcast series on finance hosted through SurgOnc Today®. In this episode, Dr. Melissa Hogg, a member of the Women in Cancer Surgery Committee, and Dr. Tari King, Chief of Breast Surgery at Dana-Farber Brigham Cancer Center discuss organizational fund flow and share insights on managing financial matters in the field.2025-03-1926 min
Ribbit RibbitAI on the Air: Mar 03's Fresh Picks from ArXivToday's AI scoop: 326 new papers on ArXiv with 72 key highlights. For more details, visit https://ribbitribbit.co/podcast00:28 - arxiv:2502.21244 Northeastern University, Brigham and Women’s Hospital, Dana-Farber Cancer Institute...00:54 - arxiv:2502.21245 Tsinghua University01:16 - arxiv:2502.20966 University of Cambridge, Siemens AG, University of Oxford01:40 - arxiv:2502.21106 Siemens Healthineers, New York University, University of Maryland Medical Center...02:08 - arxiv:2502.21123 CISPA Helmholtz Center for Information Security, Max Planck Institute, ETH Zurich...02:33 - arxiv:2502.20490 University of Arizona, Stanford University, University of Toronto...02:55 - arxiv:2502.20770 California Institute of Technology, Un...2025-03-0429 min
Marrow MastersNurse Practitioner Lisa Stewart Shares Her Extensive Experience with GVHDIn this episode, we sit down with Lisa Stewart, a nurse practitioner with more than 25 years of transplant nursing experience, currently working at the post-transplant BMT clinic at the Dana-Farber Brigham Cancer Center in Boston. Lisa provides invaluable insights into managing chronic and acute graft-versus-host disease (GVHD) and shares her expertise, stories, and advice for patients and caregivers navigating post-transplant life.Lisa describes her role in outpatient care, where the majority of her work focuses on managing chronic GVHD, a condition that is both a sign of a functioning immune system and a complex challenge. While mild...2025-01-3018 min
WEEI/NESN Jimmy Fund Radio-TelethonPhaedra Ferrini, 24, metastatic paraganglioma, Boston, with Kimberly Perez , MD, Co-Director of Dana-Farber Cancer Institute Gastrointestinal Clinical Trials Program, Senior Physician, Dana-Farber, and Assistant Professor of Medicine at Harvard Medical ScPhaedra was 14 years old and sitting in her high school nurse’s office. The nurse noticed her pupils were dilated different sizes and called Phaedra’s mom, recommending she get checked out by a doctor. At the hospital, it was discovered that they had a benign tumor, which was promptly resected. Scans a few years later at 17 indicated that there were no signs of the cancer coming back. Dr. Kimberly Perez, MD is a member of the Dana-Farber Cancer Institute/Harvard Cancer Center Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She is a Senior Physician in Me...2024-08-1409 min
WEEI/NESN Jimmy Fund Radio-TelethonCraig Bunnell, MD, Chief Medical Officer, Dana-Farber Craig Bunnell, MD, MPH, MBA, is the Morse Family Chief Medical Officer of the Dana-Farber Cancer Institute, an NCI-designated Comprehensive Cancer Center and Harvard Medical School-affiliated teaching hospital. In this role, Dr. Bunnell oversees adult and pediatric clinical services at Dana-Farber. Under his leadership, the Institute has become a leader in implementing technology to enhance patient flow, operational efficiency, and patient access. Dr. Bunnell is also a breast medical oncologist at Dana-Farber and an Associate Professor of Medicine at Harvard Medical School. He has been the principal investigator of several institutional and multicenter clinical trials and serves on...2024-08-1410 min
WEEI/NESN Jimmy Fund Radio-TelethonBarbara Ackerman, 72, lung cancer, Plymouth, with Pasi Jänne, MD, PhD, Senior Vice President for Translational Medicine, Dana-Farber Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer. In...2024-08-1410 min
WEEI/NESN Jimmy Fund Radio-TelethonJoel Davidson, 79, prostate cancer, Naples, FL, with Mark Pomerantz, MD, Clinical Director for the Lank Center for Genitourinary Oncology, Dana-FarberNine years ago, Joel was diagnosed with prostate cancer at his annual wellness exam while living in Connecticut; his best friend was his urologist at the time. He began making regular visits to Boston to get treated at Dana-Farber. Dr. Mark Pomerantz is a medical oncologist and Clinical Director for the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women's Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology...2024-08-1408 min
WEEI/NESN Jimmy Fund Radio-TelethonJaimey Buckley, 63, chronic lymphocytic leukemia, Middleboro, with Matthew Davids, MD, Dana-FarberJaimey was diagnosed with prostate cancer in 2008. He was treated and received a clean bill of health and remained cancer-free. In May 2015, a routine blood donation led to a life-changing discovery when the Red Cross director urged him to seek immediate medical attention. Jaimey was diagnosed with chronic lymphocytic leukemia (CLL), which, contrary to its typical slow progression, advanced rapidly in his case. Jaimey remained active, cycling and running to maintain his mental well-being.However, six to nine months ago, his CLL numbers began to rise again, promptingdiscussions about future treatments. Although his white...2024-08-1308 min
WEEI/NESN Jimmy Fund Radio-TelethonTina Kennedy, 34, breast cancer, Holbrook, with Erica Mayer, MD, Assistant Professor in Medicine at Harvard Medical School, Dana-FarberTina was 33 when she was diagnosed with breast cancer. She discovered a bumpnear her clavicle and went to her OGBYN who promptly sent her for a mammogram.Tina is among a growing number of young women being diagnosed with breast cancer. Tina’s treatment started with six rounds of chemotherapy, followed by a double mastectomy earlier this summer. She is currently doing some rounds of low dosage chemotherapy throughout the rest of this year and recently started radiation treatment as well. Tina works as a Government Relations Manager and works in public policy for2024-08-1310 min
WEEI/NESN Jimmy Fund Radio-TelethonRob Hale joins and says he'll match donations if we raise $775,000!!!Robert Hale, Donor Rob currently serves on Copley’s investment committee and as an entrepreneur in residence assisting the development of Copley’s portfolio companies. Rob founded Granite Telecommunications in 2002 and has grown the company into one of the largest privately held telecommunications services companies in the U.S., with revenues exceeding $1.5 billion. Rob is the founder and board chair of Fox Rock Capital, a single-family office based in Boston, founding owner of FoxRock Properties, a commercial real estate firm, and is co-owner of the NBA’s Boston Celtics and Boston Cannons of the Premier Lacrosse League. Rob lives in the Bo...2024-08-1308 min
Breastcancer.org PodcastPodcasting From the Chemo ChairCarly Fauth was diagnosed with breast cancer in January 2024. Scheduled to start chemotherapy in May, Carly decided to start a podcast called Chemo Coffee Talk, which she records from her chemo chair during her twice-monthly infusions at the Dana-Farber Brigham Cancer Center.Listen to the episode to hear Carly discuss:
how recording the podcast takes her mind off chemotherapy
how she selects her guests
what she plans to do with the podcast when her chemotherapy regimen ends
2024-08-0921 min
OncotargetImpact of Dual Immunotherapies Before Surgery in HR+/HER2-negative Breast CancerBreast cancer immunotherapy has shown promise, but its clinical efficacy remains limited, especially for hormone receptor positive (HR+)/HER2-negative breast cancer. While immune checkpoint inhibitors combined with chemotherapy have benefitted some early-stage and metastatic triple-negative breast cancer patients, HR+/HER2-negative cases have seen fewer improvements.
Recent neoadjuvant trials indicate that early-stage HR+/HER2-negative breast cancers might respond better to immunotherapy strategies that amplify tumor-infiltrating lymphocytes (TILs) through dual PD-(L)1/CTLA-4 checkpoint inhibition before surgery and chemotherapy. This approach could enhance the immune response in the tumor microenvironment and improve outcomes for this challenging breast cancer subtype.
...2024-06-2008 min
All Things Cardio-OncologyChallenges of Starting a Cardio-Oncology Clinic: Dr. Anju NohriaDr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center and a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS).
On this episode she discusses the challenges and opportunities of starting a new clinic focused on cardio-oncology care.2024-05-2918 min
OncotargetDurvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast CancerBUFFALO, NY- March 27, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”
In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, and Jennifer K. Litton from the University of Texas MD Anderson Cancer Center, Brigham and Women’s Hospital, Dana-Farber Brigham Cancer Center, and Harvard Medical School conducted a clinical trial to assess the feasibility of enrolling patients w...2024-03-2703 min
Continuum AudioSpinal Cord Neoplasms with Dr. J. Ricardo McFaline-Figueroa Tumors affecting the spine are fortunately uncommon, and may arise within the spine or metastasize from malignancies elsewhere. Effective treatment is determined by tumor type, location, and urgency. In this episode, Allison Weathers, MD, FAAN, speaks with J. Ricardo McFaline-Figueroa, MD, PhD, author of the article “Spinal Cord Neoplasms,” in the Continuum February 2024 Spinal Cord Disorders issue. Dr. Weathers is a Continuum® Audio interviewer and the associate chief medical information officer at Cleveland Clinic in Cleveland, Ohio. Dr. McFaline-Figueroa is a physician at Dana-Farber Cancer Institute and instructor in neurology at Brigham and Women...2024-02-2819 min
Biotech 2050 PodcastNext-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime MedicineSynopsis:
Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they’ve lea...2023-11-2240 min
NETWiseNETWise Episode 29: Merkel Cell Carcinoma
One of the things that sets neuroendocrine tumors apart from other kinds of cancer is that they can occur almost anywhere in the body. Those different locations — or primary sites — can mean the NET takes on different characteristics, and requires different kinds of treatment. In previous episodes of this show, we’ve talked about lung NETs, pancreatic NETs, small bowel NETs, and gynecological NETs. Today, we’re going to be talking about skin NETs. These are known as Merkel cell carcinomas. Merkel cell carcinoma can be challenging to diagnose and treat, making early detection and medical attention crucial...2023-10-2043 min
ASCO EducationCancer Topics - Oncology Practice in Low-Resource SettingsResources such as facilities, equipment, medications, and trained healthcare professionals are essential to provide proper care. Yet, many areas in the US and around the globe have challenges providing some of such resources. This ASCO Education podcast will explore oncology practice in low resource settings. Dr. Thierry Alcindor, a medical oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Dr. Richard Ingram, a Medical Oncologist at Shenandoah Oncology in Winchester, Virginia, and Chair of the Appalachian Community Cancer Alliance and Dr. Sana Al Sukhun, an Adjunct Professor of Medical Oncology and Director of Oncology Practice a...2023-10-1139 min
CareTalk: Healthcare. Unfiltered.What Dana-Farber's Shakeup Means for Cancer CareSend us a textThe Dana-Farber Cancer Institute rocked the cancer world this month by dropping its long standing partner, Brigham and Women’s in favor of building a new cancer hospital with Beth Israel. What does it mean for patients, physicians and health care costs?Is this just a local Boston story or is there broader meaning for the US healthcare system?ABOUT CARETALKCareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. He...2023-09-2919 min
Health & VeritasNita Ahuja: Epigenetics and CancerHowie and Harlan are joined by Nita Ahuja, a Yale surgeon and researcher, to discuss new methods in for detecting and treating cancers and the barriers faced by women surgeons. Harlan answers questions about an FDA panel’s finding that the decongestant phenylephrine is ineffective; Howie looks at the trends making hospital finances unsustainable. Links: “FDA clarifies results of recent advisory committee meeting on oral phenylephrine” “Phenylephrine vs. Pseudoephedrine: What’s the Difference?” “Why Has a Useless Cold Medication Been Allowed on Shelves for Years?” “Surgeon Sex and Long-Term Postoperative Outco...2023-09-2136 min
Being and DoingBeing and Doing with Dr. Daphne Haas-Kogan on Being the Light for Others - ep33"The potential to impact the world and benefit others and do good is so immense that competition is really undermining."
Daphne Haas-Kogan, MD is an American radiation oncologist. She received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology at the UCSF. Dr. Haas-Kogan spent 18 years as a radiation oncologist, researcher, and academic leader in the UCSF HDFCCC system before becoming chair of the Department of Radiation Oncology at Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.
If you like what...2023-09-2143 min
The Answers for CancersRadiotherapy for Breast Cancer Patients with Dr Daniel CagneyThis week on the podcast we are joined by Dr Daniel Cagney to discuss Radiotherapy for Breast Cancer Patients .
Dr. Daniel Cagney is clinical director of radiation oncology at Mater Private Hospital, Dublin and network director of stereotactic radiation.
Dr. Cagney’s internship and general medical training was in the Mercy Hospital Cork and Beaumont Hospital, Dublin. He did a year in medical oncology in Mater Hospital before commencing specialist training in radiation oncology in St Luke’s Hospital, Dublin. In parallel to his radiation oncology training, he received a MSc in oncol...2023-09-1830 min
Speaking of SurgOncImpact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast CancerRick Greene, MD, and Tari King, MD, FSSO, discuss findings generated from central path review of a large series of patients treated with neoadjuvant chemotherapy and surgery regarding the pattern of residual tumor in the breast and its related prognostic significance. Dr. King is the senior author of, “Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer.” Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the vice chair of mul...2023-09-1215 min
Lung Cancer ConsideredLive from WCLC: Monday HighlightsMonday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Emi Bossio, a patient research advocate and board member of Lung Cancer Canada adds her...2023-09-1154 min
Health Professional Radio - PodcastGenmab and AbbVie Present New Epcoritamab Data at EHA 2023Dr. Reid Merryman, MD, an attending physician in the Lymphoma Program at the Dana-Farber Cancer Institute discusses Genmab and AbbVie's preliminary data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in patients across B-Cell lymphomas that were presented at the European Hematology Association's (EHA) Annual Meeting 2023. Read the abstract here.
#EPCORE
Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Car...2023-09-0707 min
WEEI/NESN Jimmy Fund Radio-TelethonMeghan Hesketh, 28, breast cancer, Boston, with Ann Partridge, MD, MPH, Founder and Director, Program for Young Adults with Breast CancerAfter difficulty breathing, Megan subsequently tested positive for COVID, which doctors initially thought was the cause of her symptoms. But her oxygen saturation, or the balance of oxygen in her blood, remained low, so she underwent additional testing. Then, a chest x-ray revealed two liters of fluid in her lungs. After a fusion biopsy, she was officially diagnosed with Stage 4 breast cancer in June of 2022. Since then, Megan has been treated with hormonal therapy and continues to receivetreatment today. She also has tremendous support from her family members, both of whom also work in the...2023-08-3007 min
WEEI/NESN Jimmy Fund Radio-TelethonBarry Nelson, 70, lung cancer, Boston, with Chris Lathan, MD, MS, MPH, Chief Clinical Access and Equity Officer, Faculty Director for Cancer Care Equity, Dana-FarberIn 2012, Barry noticed some swelling on his neck, so he made an appointment to see his primary care physician. An x-ray and CT scan lead to follow-up appointments with various specialists until he was diagnosed with Stage 3B non-small cell lung cancer. Barry was initially going to get treatment at another institution but stopped at Dana-Farber to get a second opinion from Dr. Lathan. He recalls Dr. Lathan telling him they’d use all the tools in the toolbox and fight as hard as he could. From there, Barry knew he was in the right place. The tr...2023-08-3010 min
WEEI/NESN Jimmy Fund Radio-TelethonDana Mohrlein, 35, astrocytoma, Niantic CT, with David Reardon, MD Clinical Director, Center of Neuro-Oncology, Dana-FarberDana Mohrlein, 35, astrocytoma, Niantic CT, with David Reardon, MD Clinical Director, Center of Neuro-Oncology, Dana-Farber In college, Dana thought she may have vertigo because of all her headaches, but after aseizure at her first security job, she learned she needed emergency brain surgery. After surgeryat her local hospital, she pursued a second opinion at Dana-Farber and has continued herjourney from there since. She had two additional brain surgeries that same summer atBrigham-Women's Hospital. Shortly after, she started high dose radiation locally, in partnershipwith Dana-Farber, and did 11 months...2023-08-3010 min
WEEI/NESN Jimmy Fund Radio-TelethonElle Simone Scott joins Joe & Will from the booth!As a cast member/chef on the television series “America’s Test Kitchen,” and host of its companion podcast “The Walk-In,” Elle Simone Scott delights in sharing her expertise and recipes. The Boston-based celebrity chef and food stylist is also a role model, as founder and president of SheChef, Inc., a professional networking organization for fellow women chefs of color seeking success in the food and beverage, media, and hospitality industries. Elle found a new doctor once she arrived in Boston, got another ultrasound, and learned she had a cyst with cancerous concerns on her right ovary. Her doctor...2023-08-3005 min
WEEI/NESN Jimmy Fund Radio-TelethonKeith Johnson, 68, stomach cancer, Brookline, with Ben Schlechter, MD, Senior Physician, Gastrointestinal Cancer, Dana-FarberAfter initially experiencing mild symptoms such as intolerance for spicy and acidic foods and abdomen soreness, Keith Johnson, a neurologist at Mass General Brigham, went to see his primary care physician when he noticed that these symptoms had worsened after a few months. He was diagnosed with stomach adenocarcinoma or stomach cancer in March 2021 and was started on a combination of chemotherapy and immunotherapy at Dana-Farber Cancer Institute under the care of his oncologist Dr. Ben Schlechter. Most cancers of the stomach (about 90% to 95%) are adenocarcinomas. These cancers develop from the gland cells in the innermost lining...2023-08-2906 min
WEEI/NESN Jimmy Fund Radio-TelethonMary Worthington Kachadurian, 65, follicular lymphoma, Boston, with Ann S. LaCasce, MD, MMSc, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/OncologyBlood in her urine lead Mary to get a kidney stone scan, but incidentally revealed that she had lymphoma. She immediately called Dana-Farber and was connected with the Cancer Diagnostic Service at Dana-Farber Brigham Cancer Center, which was new at the time of her lymphoma finding in 2018. The staff there cared for and led her through an expedited process to an official diagnosis of follicular lymphoma. At the same time, Mary had been training for the 2018 Pan Mass Challenge. She started chemotherapy in the in the fall of 2018, every 3 weeks for 6 cycles, because the cancer had become...2023-08-2908 min
Johns Hopkins Kimmel Cancer Center PodcastsOn Target with Dr Akila Viswanathan - Palliative Care for Seminars in Radiation OncologyDr Akila Viswanathan and Dr Tracy Balboni from Harvard Medical School and Dana-Farber/Brigham and Women's Cancer Center discuss the latest developments in palliative care for Seminars in Radiation Oncology.2023-07-2523 minJohns Hopkins Kimmel Cancer CenterOn Target with Dr Akila Viswanathan - Palliative Care for Seminars in Radiation OncologyDr Akila Viswanathan and Dr Tracy Balboni from Harvard Medical School and Dana-Farber/Brigham and Women's Cancer Center discuss the latest developments in palliative care for Seminars in Radiation Oncology.2023-07-2523 min
Hopkins Biotech PodcastBoston Biotech Series: Building a Drug Development Platform on New Biology with Isaac Klein of Dewpoint TherapeuticsDr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines targeting biomolecular condensates.Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical School, as well as a scientist at the Whitehead Institute of MIT. He holds a Ph.D. in Biology...2023-07-1738 min
AUANews Inside TractVoices: FUTURE in Urology Recap #1Today’s podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Dr. Quoc-Dien Trinh, associate professor of surgery at Harvard Medical School; chief of urology at Brigham and Women's Faulkner Hospital and co-director of the prostate cancer program at the Dana-Farber/Brigham and Women's Cancer Center, sits down with his mentee, Jameshisa Alexander, first year medical student at the Morehouse School of Medicine, to discuss the inaugural FUTURE in Urology Program held in conjunction with AUA's Annual Meeting in April 2023.2023-06-2717 min
The Medicine Mentors PodcastBuilding a Mentorship Mosaic with Dr. Ann LaCasceAnn LaCasce, MD, is the Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and an Associate Professor of Medicine at Harvard Medical School. Dr. LaCasce completed her medical school from Tufts University and residency in Internal Medicine at Brigham and Women’s Hospital where she later served as Chief Medical Resident, followed by a fellowship in Hematology/Oncology at the Dana-Farber Cancer Institute. She is a nationally renowned lymphoma specialist, chairs the steering committee for Women in Lymphoma and is currently serving as Chair-elect of the Lymphoma Research Foundation. “You’re never going to find one person who can...2023-03-0820 min
Conversations in Lung Cancer ResearchCelebrating Female Leadership in Medical ResearchIn this TOGA Podcast, and on International Women’s Day 2023, we celebrate female leadership in medical research. We explore the challenges and success pathways across different career stages for women who work in medical oncology and clinical research. Associate Professor Prunella Blinman, head of the medical oncology department at Concord Hospital and past chair of the Medical Oncology Group of Australia, is joined by Assistant Professor Narjust Florez, Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center; Professor Lorraine Chantrill, medical oncologist and Head of Service for Medical Oncology across th...2023-03-0831 min
VJOncology PodcastKey data and hot topics in prostate cancer at ASCO GU 2023In this episode, we’ll be hearing from GU cancer experts about some of the biggest prostate cancer data presented at the ASCO Genitourinary Cancers Symposium 2023, including TRITON3, CheckMate650, and FORMULA-509. We’ll also be hearing perspectives on some of the hot topics in the field, such as treatment sequencing and combination therapies, unanswered questions for the use of PSMA PET in the staging of disease, and the use of active surveillance in localized prostate cancer.
Join Alan Bryce, MD, Mayo Clinic, Rochester, MN, Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, Paul Nguy...2023-03-0320 min
VJOncology PodcastKey data and hot topics in prostate cancer at ASCO GU 2023In this episode, we’ll be hearing from GU cancer experts about some of the biggest prostate cancer data presented at the ASCO Genitourinary Cancers Symposium 2023, including TRITON3, CheckMate650, and FORMULA-509. We’ll also be hearing perspectives on some of the hot topics in the field, such as treatment sequencing and combination therapies, unanswered questions for the use of PSMA PET in the staging of disease, and the use of active surveillance in localized prostate cancer.
Join Alan Bryce, MD, Mayo Clinic, Rochester, MN, Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, P...2023-03-0320 min
CLOT ConversationsDOACs vs VKAs in thrombotic APS - Dr Jean Connors & Dr Behnood BikdeliSend us a textIn this interview, two of the authors of the paper Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials, Dr Jean Connors and Dr Benhood Bikdeli, provide listeners with an overview of their systematic review and meta-analysis that evaluated the efficacy and safety of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in patients with thrombotic antiphospholipid syndrome. The authors searched through three databases (PubMed, EMBASE, and Cochrane Central Register of Controlled Trials) and found four eligible randomized controlled trials with a total...2023-02-0320 min
CANCER BUZZEngaging Patients with Small Cell Lung Cancer in Clinical TrialsMany patients with SCLC have a high symptom burden, poor prognosis, adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. Clinical trials are taking place across the country for patients with all stages of small cell lung cancer. CANCER BUZZ spoke to David Waterhouse, MD, MPH, Medical Oncologist and Hematologist at the Dana-Farber Brigham Cancer Center, Milford Regional Medical Center in Milford, MA. Hear how to engage patients in clinical trials and address barriers. “Eighty-five percent (85%) of cancer care is being done in the community, not at academic centers such as ours. And so, you have t...2022-11-2209 min
Prostate Cancer AwareRadiation Oncology Teamwork with Dr. Peter OrioOn this episode host & prostate cancer survivor Jonathan Chance talks with Dr. Peter Orio who is the Vice Chair of Network Operations at the Dana-Farber | Brigham Cancer Center Department of Radiation Oncology about radiation oncology teamwork for the treatment of prostate cancer. Dr. Orio also discusses why men should not to ignore prostate cancer. Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about h...2022-11-1306 min
Causes or CuresEvidence for an Emerging Epidemic of Cancer in Young People, with Dr. Shuji OginoSend us a textIn this Causes or Cures episode, Dr. Eeks chats with Dr. Shuji Ogino about his recent paper published in Nature Reviews, Clinical Oncology, titled "Is early-onset cancer an emerging global epidemic? Current evidence and future implications." In the podcast, Dr. Ogino discusses what "early onset" means, what types of cancer are showing up earlier in people less than 50 years of age, and the evidence and data that supports this trend. He discusses how exposures early in life and in utero may be contributing to early-onset cancer in young people ( in their thirties...2022-11-0257 min